80842Development of home blood monitoring test for cancer patients to reduce need for hospital visitsClosedCollaborative R&DInnovate UKThe coronavirus pandemic of 2020 has had a huge impact on the lives of millions around the country. A particular challenge has been faced by cancer patients, who have been forced to miss regular checkups and tests over recent months because of their elevated risks of infection (the immune systems of cancer - and especially chemotherapy - patients are often suppressed, making them more vulnerable to infections like COVID-19) and due to the redeployment of healthcare staff to fight the COVID challenge. Much like the transformation that occurred following the introduction of the home diabetes test, what is needed are new innovative methods of home monitoring of cancer patients (especially those undergoing chemotherapy) to reduce the number of necessary visits to hospital that chemo patients must make, reduce the healthcare burden on the NHS, lower the carbon footprint and make the lives of chemo patients and their families a little bit easier. Seroxo is addressing this need through redeployment of its proprietary Leukocyte _ImmunoTest_(TM) ten-minute, finger-prick blood test into this space and development of an accompanying smartphone App. The key innovations in this project will be in demonstrating the usefulness of the test for monitoring the immune systems of chemotherapy patients and the development of a smartphone app that will monitor and display results over time for use by both clinician and patient. This will benefit the lives of the over 100,000 patients undergoing chemotherapy each year in the UK, and will benefit healthcare systems by reducing numbers of monitoring checkups, making the provision of world-leading healthcare and support in the UK even more efficient.